Question 1
Does Maidstone and Tunbridge Wells NHS Trust have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?
Question 2
Does Maidstone and Tunbridge Wells NHS Trust have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?
a. Sotorasib (Lumykras)
b. Entrectinib (Rozlytrek)
c. Larotrectinib (Vitrakvi)
d. Dabrafenib (Tafinlar)
e. Trametinib (Mekinist)
f. Capmatinib (Tabrecta)
g. Tepotinib (Tepmetko)
h. Bevacizumab (Avastin)
i. Ramucirumab (Cyramza)
j. Atezolizumab (Tecentriq)
k. Durvalumab (Imfinzi)
l. Cemiplimab- (Libtayo)
m. Nivolumab (Opdivo)
n. Pembrolizumab (Keytruda)
o. Ipilimumab (Yervoy)
p. Afatinib (Giotrif)
q. Dacomitinib (Vizimpro)
r. Erlotinib (Tarceva)
s. Gefitinib (Iressa)
t. Osimertinib (Tagrisso)
u. Amivantamab (Rybrevant)
v. Mobocertinib (Exkivity)
w. trastuzumab deruxtecan (Enhertu)
x. Alectinib (Alecensa)
y. Brigatinib (Alunbrig)
z. Ceritinib (Zykadia)
aa. Crizotinib (Xalkori)
bb. Lorlatinib (Lorviqua)
cc. Entrectinib (Rozlytrek)
dd. Pralsetinib (Gavreto)
ee. Selpercatinib (Retsevmo)
ff. Nintedanib (Vargatef®)
Question 3
If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?
Question 4
Does Maidstone and Tunbridge Wells NHS Trust have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?
Question 5
Is Maidstone and Tunbridge Wells NHS Trust part of a Cancer alliance or network, if so which ones?

Local Treatment Guidelines Non-Small Cell Lung Cancer.020823.docx